Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase 1/1b trial of PUR1900 for treatment of fungal infections in cystic fibrosis patients

Next Previous
Trial Profile

A phase 1/1b trial of PUR1900 for treatment of fungal infections in cystic fibrosis patients

Status: Planning
Phase of Trial: Phase I

Latest Information Update: 20 Mar 2017

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Itraconazole (Primary)
  • Indications Cystic fibrosis-associated respiratory tract infections
  • Focus Adverse reactions

    • Most Recent Events

    • 10 Mar 2017 According to a Pulmatrix media release, the company plans to initiate this study in 2017.
    • 10 Mar 2017 According to a Pulmatrix media release, the company plans to read out the data from trial in 2017.
    • 17 Jan 2017 According to a Pulmatrix media release, the U.S. Food & Drug Administration has designated PUR1900 as a Qualified Infectious Disease Product for the treatment of fungal infections in the lungs of cystic fibrosis patients.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top